🔎 Trials Near Me

Beranda › Leukemia Biphenotypic Akut › Maryland

Uji klinis Leukemia Biphenotypic Akut di Maryland

4 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi di Maryland.

Kota di Maryland

Teks studi resmi (Bahasa Inggris)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • dan 1 lainnya
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Johns Hopkins University, Baltimore
  • National Cancer Institute, Pediatric Oncology Branch, Bethesda
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.